Journal
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 7, Issue 1, Pages 19-34Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152007779314062
Keywords
Anticancer drug; Platinum complex; Sulfur; Platinum-sulfur interaction; Chemotherapy; Chemoprotectant; Resistance; Sulfur-containing molecules
Categories
Funding
- National Science Foundation of China [20231010, 20228102, 30370351]
- China Postdoctoral Science Foundation [2003034374]
- Natural Science Foundation of Jiangsu Province [BK 2005209]
Ask authors/readers for more resources
Sulfur manifests its influence on platinum anticancer chemotherapy in two aspects: endogenous sulfur-containing molecules such as cysteine, methionine, glutathione, metallothionein and albumin affect the metabolism of platinum drugs and exert adverse effects on the therapeutic efficacy; exogenous congeners such as amifostine (WR-2721) and dimesna (BNP7787) mitigate the toxic side effects of platinum drugs and serve as chemoprotectants. The platinum-sulfur interactions are ubiquitous in the human body and many occurrences encountered during platinum chemotherapy such as uptake, excretion, resistance, and toxicity are related to them. Thus, sulfur-containing molecules play significant roles in the anticancer mechanism of platinum drugs. In this review, the platinum-sulfur interactions are summarized in detail, which may be important for efficient clinical use of the existing platinum agents and beneficial to the rational design of new generation of platinum-based anticancer drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available